Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: John Zwiener who wrote (2175)	8/1/1998 12:26:00 AM
From: TinaK	Read Replies (1) \| Respond to of 4676

Sorry, didn't respond earlier but was at meeting. Phase I was published in J Pharmacol. Exp. Ther. Phase II was published in Gastroenterology. The data was also presented at a couple of conferences. You are correct in stating the data is limited and that ultimately it may prove that it is not superior to Avakine. However two things make me enthusiastic. First if you look at the Avakine data published in NEJM you notice that the patient group was not uniform which is untrue of the ISIP study. The patients in the ISIP study unlike the Avakine study were all steroid dependent (more difficult to treat). Second treatment with 2302 allowed a third of the patients to be weened off the steroids this did not occur in the Avakine treated group. This is a major advantage. The steroid saving makes me believe that if the data holds up 2302 will be the prefered treatment. 2922 causes irreversible peripheral field deficits at 300 micrograms. This is a RARE but serious side effect. This data is available in a review article of localized CMV retinitis treatment published in 1996. There are two possible explanations, but the more likely is that it is a nonantisense effect. This is important because 330 is the dosage used in the CS9 trial which is the biweekly/monthly maintenence treatment trial. (150 was the dosage in the first phase III trial). For the person interested in Antivirals, the company changed its name when it aquired ITC it is now AVI Biopharm.